98%
921
2 minutes
20
Adeno-associated virus type 2 (AAV) is known to establish latency by preferential integration in human chromosome 19q13.42. The AAV non-structural protein Rep appears to target a site called AAVS1 by simultaneously binding to Rep-binding sites (RBS) present on the AAV genome and within AAVS1. In the absence of Rep, as is the case with AAV vectors, chromosomal integration is rare and random. For a genome-wide survey of wildtype AAV integration a linker-selection-mediated (LSM)-PCR strategy was designed to retrieve AAV-chromosomal junctions. DNA sequence determination revealed wildtype AAV integration sites scattered over the entire human genome. The bioinformatic analysis of these integration sites compared to those of rep-deficient AAV vectors revealed a highly significant overrepresentation of integration events near to consensus RBS. Integration hotspots included AAVS1 with 10% of total events. Novel hotspots near consensus RBS were identified on chromosome 5p13.3 denoted AAVS2 and on chromsome 3p24.3 denoted AAVS3. AAVS2 displayed seven independent junctions clustered within only 14 bp of a consensus RBS which proved to bind Rep in vitro similar to the RBS in AAVS3. Expression of Rep in the presence of rep-deficient AAV vectors shifted targeting preferences from random integration back to the neighbourhood of consensus RBS at hotspots and numerous additional sites in the human genome. In summary, targeted AAV integration is not as specific for AAVS1 as previously assumed. Rather, Rep targets AAV to integrate into open chromatin regions in the reach of various, consensus RBS homologues in the human genome.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900306 | PMC |
http://dx.doi.org/10.1371/journal.ppat.1000985 | DOI Listing |
Gland Surg
March 2025
Department of Plastic and Reconstructive Surgery, Korea University Anam Hospital, Seoul, Republic of Korea.
Background: Red breast syndrome (RBS) is represented as idiopathic cutaneous erythema overlying the acellular dermal matrix (ADM) after implant-based breast reconstruction without other signs and symptoms of infection. Although a number of etiologies including lymphatic disruption, delayed hypersensitivity reaction to ADM, and residual DNA within ADM have been suggested for RBS, consensus regarding risk factors and treatment for RBS has been reached yet. Thus, the aim of this study was to find risk factors for RBS and introduce our experience of successful treatment of RBS.
View Article and Find Full Text PDFEuropace
March 2025
Clinical Cardiac Academic Group, Genetic and Cardiovascular Sciences Institute, City-St George's University of London, London, UK.
Atrial fibrillation (AF) is one of the most common cardiac diseases and a complicating comorbidity for multiple associated diseases. Many clinical decisions regarding AF are currently based on the binary recognition of AF being present or absent with the categorical appraisal of AF as continued or intermittent. Assessment of AF in clinical trials is largely limited to the time to (first) detection of an AF episode.
View Article and Find Full Text PDFAnn Plast Surg
February 2025
Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA.
Background: Red breast syndrome (RBS) has been noted in past literature as a possible complication of implant-based breast reconstruction (IBBR) with the use of acellular dermal matrices (ADMs). Since its first appearance in 2009, RBS has drawn growing medical attention with reported incidence ranging from 7%-9%. There has been a noted decrease in the emergence of RBS despite its inclusion among the analyzed complications in a number of studies.
View Article and Find Full Text PDFThromb Haemost
September 2025
St. George's University of London, London, United Kingdom.
Europace
March 2024
Atrial Fibrillation NETwork (AFNET), Muenster, Germany.
Aims: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA).
Methods And Results: Eighty-three international experts met in Münster for 2 days in September 2023.